→ Boston-based Pieris $PIRS has optioned a licensing pact giving ASKA Pharmaceutical development and commercialization rights for the anemia drug PRS-080 in Japan and certain other Asian markets. Pieris gets a $2.75 million option payment on the deal, and if ASKA agrees to formally sign on after looking over Phase IIa data, then Pieris will be in line for up to $80 million in milestones. “We are pleased to have found a very committed partner for PRS-080 in a key Asian market,” said Stephen Yoder, the CEO of Pieris. “Importantly, this deal enables us to invest in improving drug manufacturing efficiencies while conducting our Phase 2a trial to enable seamless drug supply for future clinical studies by ASKA and other partners we may seek in other territories, as we focus our proprietary pipeline in immunology-related areas for long-term value creation.”
→ Israel’s Pharma Two B has raised $30 million for its work on a new Parkinson’s drug. Much of the money is being earmarked to fund a pivotal study of P2B001, with some reserved for adding products to the pipeline. The Israel Biotech Fund led the round and ex-Pfizer CEO Jeff Kindler will be going onto the biotech’s board.
→ Bermuda-based Sellas has in-licensed Advaxis’ Lm-based antigen delivery technology for use with its blood cancer drug galinpepimut-S. There’s no upfront in the agreement, but Advaxis is in line for up to $358 million in milestones. Said Advaxis CEO Daniel J. O’Connor: “Sellas’ proprietary galinpepimut-S therapy has already demonstrated clinical benefit and a strong immune response against WT1 expressing cancer cells. We believe that the use of our proprietary Lm-based antigen delivery technology with Sellas’ proprietary technology could result in a very compelling WT1-targeted cancer immunotherapy.”
→ Research Triangle Park-based BioCryst $BCRX posted a positive set of interim data for its Phase II study of BCX7353 in reducing attacks among HAE patients. But concerns about the drug’s competitive stance with rival therapies ended up driving down its share price on Monday morning.
→ Ampio Pharma $AMPE shares were eviscerated by late-stage pain drug failures last year, sending the microcap biotech into penny stock land. Today the biotech says that it struck a deal with the FDA, agreeing to mount a new 12-week study of the drug as it works to line up a BLA.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription